A Phase II Study of Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome

Update Il y a 4 ans
Reference: EUCTR2007-002532-28

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to determine the Hematologic Improvement (HI) rate during the 12-month study period with rATG (Thymoglobulin), as defined by the IWG and published in 2006 by Cheson and colleagues


Inclusion criteria

  • Low And Intermediate-1 Risk Myelodysplastic Syndrome in adult patients 60 years or younger